Aerie Pharmaceuticals to Present at Three Investor Conferences in March

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in March.

• Cowen and Company 37th Annual Health Care Conference
  • Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
  • Presentation Type: Corporate Overview
  • Presentation Date: Tuesday, March 7, 2017
  • Presentation Time: 10:00am E.T.
  • Location: Boston, MA
• 29th Annual ROTH Conference
  • Presenter: Thomas Mitro, President and Chief Operating Officer
  • Presentation Type: Corporate Overview
  • Presentation Date: Tuesday, March 14, 2017
  • Presentation Time: 1:30pm P.T.
  • Location: Dana Point, CA
• Oppenheimer's 27th Annual Healthcare Conference
  • Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer
  • Presentation Type: Fireside
  • Presentation Date: Tuesday, March 21, 2017
  • Presentation Time: 2:45pm E.T.
  • Location: New York, NY

The presentations and fireside discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil ophthalmic solution) 0.02% was resubmitted in February 2017. The second product candidate, RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of RhopressaTM and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM NDA filing is expected to take place in late 2017 or early 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170302005086/en/

Aerie Pharmaceuticals
Richard Rubino, 908-947-3540
[email protected]
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Ami Bavishi, 212-213-0006
[email protected]

Source: Aerie Pharmaceuticals, Inc.

You May Also Be Interested In

• XRP Price Prediction: ETFs Add $38 Million in Two Days as Pepeto 100x Presale Heats Up
• Best Crypto To Invest In: AlphaPepe Passes $2.8M as Binance Listing Rumours Build Before the 5th CEX Reveal
• UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million